1 Triadafilopoulos G, Patti MG, Gullo Ret al. . The Kagoshima consensus on esophageal achalasia Dis Esophagus. 2012;25:337-348.
2 Sadowski D, Ackah F, Jiang B, Svenson L. Achalasia: incidence, prevalence and survival. A population‐based study Neurogastroenterol Motil. 2010;22:e256-e261.
3 Farrokhi F, Vaezi MF. Idiopathic (primary) achalasia Orphanet J Rare Dis. 2007;2:38.
4 Ghoshal UC, Daschakraborty SB, Singh R. Pathogenesis of achalasia cardia World journal of gastroenterology : WJG. 2012;18:3050-3057.
5 Ates F, Vaezi MF. The pathogenesis and management of achalasia: current status and future directions Gut and liver. 2015;9:449.
6 Furuzawa-Carballeda J, Torres-Landa S, Valdovinos MÁ, Coss-Adame E, del Campo LAM, Torres-Villalobos G. New insights into the pathophysiology of achalasia and implications for future treatment World J. Gastroenterol. 2016;22:7892; Park W, Vaezi MF. Etiology and pathogenesis of achalasia: the current understanding Am J Gastroenterol. 2005;100:1404-1414.
7 Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function Cell. 2004;116:281-297.
8 Furer V, Greenberg JD, Attur M, Abramson SB, Pillinger MH. The role of microRNA in rheumatoid arthritis and other autoimmune diseases Clin. Immunol. 2010;136:1-15.
9 Fang Y, Fang D, Hu J. MicroRNA and its roles in esophageal cancer Med Sci Monit. 2012;18:RA22-RA30.
10 Singh RP, Massachi I, Manickavel Set al. . The role of miRNA in inflammation and autoimmunity Autoimmun. Rev. 2013;12:1160-1165;Tahamtan A, Inchley CS, Marzban Met al. . The role of microRNAs in respiratory viral infection: friend or foe? REV MED VIROL. 2016;26:389-407.
11 Wang C, Ji B, Cheng B, Chen J, Bai B. Neuroprotection of microRNA in neurological disorders (Review) Biomed Rep. 2014;2:611-619.
12 Kye MJ, Inês do Carmo GG. The role of miRNA in motor neuron disease FRONT CELL NEUROSCI. 2014;8.
13 Hasanzadeh A, Mikaeli J, Elahi E, Mehrabi N, Etemadi A, Malekzadeh R. Demographic, clinical features and treatment outcomes in 700 achalasia patients in Iran Middle East journal of digestive diseases. 2010;2:91.
14 Bolger A, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30: btu170. 2014.
15 Friedländer MR, Mackowiak SD, Li N, Chen W, Rajewsky N. miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades Nucleic Acids Res. 2011;40:37-52.
16 Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data Nucleic Acids Res. 2013;42:D68-D73.
17 Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition Nature Genet. 2007;39:1278.
18 Sturm M, Hackenberg M, Langenberger D, Frishman D. TargetSpy: a supervised machine learning approach for microRNA target prediction BMC bioinformatics. 2010;11:292.
19 Rehmsmeier M, Steffen P, Höchsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes RNA. 2004;10:1507-1517.
20 Mohammadi-Yeganeh S, Paryan M, Samiee SMet al. . Development of a robust, low cost stem-loop real-time quantification PCR technique for miRNA expression analysis Mol Biol Rep. 2013;40:3665-3674.
21 Vantrappen G, Hellemans J. Treatment of achalasia and related motor disorders Gastroenterology. 1980;79:144-154.
22 Kahrilas PJ, Bredenoord A, Fox Met al. . The Chicago Classification of esophageal motility disorders, v3. 0 Neurogastroenterol Motil. 2015;27:160-174.
23 Shoji H, Isomoto H, Yoshida Aet al. . MicroRNA-130a is highly expressed in the esophageal mucosa of achalasia patients Exp Ther Med. 2017;14:898-904.
24 Qualman SJ, Haupt HM, Yang P, Hamilton SR. Esophageal Lewy bodies associated with ganglion cell loss in achalasia.Similarity to Parkinson's disease. Gastroenterology. 1984;87:848-856.
25 Hirano I. Pathophysiology of achalasia and diffuse esophageal spasm GI Motility online. 2006.
26 Sodikoff JB, Lo AA, Shetuni BB, Kahrilas PJ, Yang GY, Pandolfino JE. Histopathologic patterns among achalasia subtypes Neurogastroenterol Motil. 2016;28:139-145.
27 Kahrilas PJ, Boeckxstaens G. The spectrum of achalasia: lessons from studies of pathophysiology and high-resolution manometry Gastroenterology. 2013;145:954-965.
28 Chen D-l, Zhang D-s, Lu Y-xet al. . microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer Oncotarget. 2015;6:10868.
29 Vychytilova-Faltejskova P, Kiss I, Klusova Set al. . MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma Diagn Pathol. 2015;10:1.
30 Wang X, Li M, Wang Zet al. . Silencing of long noncoding RNA MALAT1 by miR-101 and miR-217 inhibits proliferation, migration, and invasion of esophageal squamous cell carcinoma cells J Biol Chem. 2015;290:3925-3935.
31 Wang B, Shen Z-l, Jiang K-wet al. . MicroRNA-217 functions as a prognosis predictor and inhibits colorectal cancer cell proliferation and invasion via an AEG-1 dependent mechanism BMC cancer. 2015;15:1.
32 Wang R-T, Xu M, Xu C-X, Song Z-G, Jin H. Decreased Expression of miR216a Contributes to Non–Small-Cell Lung Cancer Progression Clin Cancer Res. 2014;20:4705-4716.
33 Dong S, Yin H, Dong Cet al. . Predictive Value of Plasma MicroRNA-216a/b in the Diagnosis of Esophageal Squamous Cell Carcinoma Dis Markers. 2016;2016.
34 Deng M, Tang H, Zhou Yet al. . miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma J Cell Sci. 2011;124:2997-3005.
35 Liu F, Zhou S, Deng Yet al. . MiR-216b is involved in pathogenesis and progression of hepatocellular carcinoma through HBx-miR-216b-IGF2BP2 signaling pathway Cell Death Dis. 2015;6:e1670.
36 Grasso M, Piscopo P, Confaloni A, Denti MA. Circulating miRNAs as biomarkers for neurodegenerative disorders Molecules. 2014;19:6891-6910.
37 Martínez-Ramos R, García-Lozano J, Lucena Jet al. . Differential expression pattern of microRNAs in CD4+ and CD19+ cells from asymptomatic patients with systemic lupus erythematosus Lupus. 2014;23:353-359.
38 Morris L, Veeriah S, Chan T. Genetic determinants at the interface of cancer and neurodegenerative disease Oncogene. 2010;29:3453-3464; Li P, Mao WM, Zheng ZG, Dong ZM, Ling ZQ. Down-regulation of PTEN expression modulated by dysregulated miR-21 contributes to the progression of esophageal cancer Dig Dis Sci. 2013;58:3483-3493.
39 Kim D, Nguyen MD, Dobbin MMet al. . SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis EMBO J. 2007;26:3169-3179.
40 Ruiz-de-León A, Mendoza J, Sevilla-Mantilla Cet al. . Myenteric antiplexus antibodies and class II HLA in achalasia Dig Dis Sci. 2002;47:15-19.
41 Palmieri O, Mazza T, Merla Aet al. . Gene expression of muscular and neuronal pathways is cooperatively dysregulated in patients with idiopathic achalasia Sci. Rep. 2016;6:31549.
42 De León A, De La Serna J, Santiago Jet al. . Association between idiopathic achalasia and IL23R gene Journal of neurogastroenterology and motility. 2010;22:734-e218.
43 Lian J, Tian H, Liu Let al. . Downregulation of microRNA-383 is associated with male infertility and promotes testicular embryonal carcinoma cell proliferation by targeting IRF1 Cell Death Dis. 2010;1:e94; Xu D, Ma P, Gao G, Gui Y, Niu X, Jin B. MicroRNA-383 expression regulates proliferation, migration, invasion, and apoptosis in human glioma cells Tumor Biology. 2015;36:7743-7753; Xu Z, Zeng X, Tian Det al. . MicroRNA-383 inhibits anchorage-independent growth and induces cell cycle arrest of glioma cells by targeting CCND1 Biochem. Biophys. Res. Commun. 2014;453:833-838; Li KKW, Pang JCS, Lau KMet al. . MiR‐383 is Downregulated in Medulloblastoma and Targets Peroxiredoxin 3 (PRDX3) Brain Pathol. 2013;23:413-425.
44 Ahmad A, Zhang W, Wu M, Tan S, Zhu T. Tumor-suppressive miRNA-135a inhibits breast cancer cell proliferation by targeting ELK1 and ELK3 oncogenes Genes & genomics. 2018;40:243-251; Yamada Y, Hidaka H, Seki Net al. . Tumor‐suppressive microRNA‐135a inhibits cancer cell proliferation by targeting the c‐MYC oncogene in renal cell carcinoma Cancer Sci. 2013;104:304-312.
45 Dughera L, Chiaverina M, Cacciotella L, Cisarò F. Management of achalasia Clin Exp Gastroenterol. 2011;4:33.